Literature DB >> 11149247

Single or continuous injection of glial cell line-derived neurotrophic factor in the striatum induces recovery of the nigrostriatal dopaminergic system.

M Aoi1, I Date, S Tomita, T Ohmoto.   

Abstract

Glial cell line-derived neurotrophic factor (GDNF) is a member of the transforming growth factor beta superfamily and acts as a neurotrophic factor for the nigrostriatal dopaminergic system. GDNF at a dose of 100 micrograms was injected stereotactically into the striatum of Sprague-Dawley rats that had been treated with intrastriatal 6-hydroxydopamine (6-OHDA) injection four weeks earlier. Immunocytochemical and behavioral analyses showed significant recovery of the nigrostriatal dopaminergic system after a single GDNF injection or continuous GDNF injection. Immunocytochemical and behavioral study showed that there was no significant difference between the results obtained from the two different injection methods. This result demonstrates the potential usefulness of GDNF for the treatment of Parkinson's disease.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11149247     DOI: 10.1080/01616412.2000.11740761

Source DB:  PubMed          Journal:  Neurol Res        ISSN: 0161-6412            Impact factor:   2.448


  4 in total

1.  Glial cell line-derived neurotrophic factor protects midbrain dopaminergic neurons against lipopolysaccharide neurotoxicity.

Authors:  Bin Xing; Tao Xin; Lingling Zhao; Randy L Hunter; Yan Chen; Guoying Bing
Journal:  J Neuroimmunol       Date:  2010-05-14       Impact factor: 3.478

Review 2.  Challenges and promises in the development of neurotrophic factor-based therapies for Parkinson's disease.

Authors:  Tiago Martins Rodrigues; André Jerónimo-Santos; Tiago Fleming Outeiro; Ana Maria Sebastião; Maria José Diógenes
Journal:  Drugs Aging       Date:  2014-04       Impact factor: 3.923

3.  The orphan nuclear receptor Nurr1 agonist amodiaquine mediates neuroprotective effects in 6-OHDA Parkinson's disease animal model by enhancing the phosphorylation of P38 mitogen-activated kinase but not PI3K/AKT signaling pathway.

Authors:  Piniel Alphayo Kambey; Ma Chengcheng; Guo Xiaoxiao; Ayanlaja Abiola Abdulrahman; Kouminin Kanwore; Iqra Nadeem; Wu Jiao; Dianshuai Gao
Journal:  Metab Brain Dis       Date:  2021-01-28       Impact factor: 3.584

Review 4.  Neuroprotective Surgical Strategies in Parkinson's Disease: Role of Preclinical Data.

Authors:  Napoleon Torres; Jenny Molet; Cecile Moro; John Mitrofanis; Alim Louis Benabid
Journal:  Int J Mol Sci       Date:  2017-10-20       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.